• print
  • mail
  • Home
  • Science
  • Pipeline

  • Overview
  • Pipeline
  • Clinical Trials
  • Ethical Research
  • R&D Vision
  • Resource Library
Pipeline
This information is current as of February 9, 2011. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
  • Phase 1
  • Phase 2
  • Phase 3
Phase 1
antibody
AMG 139
Inflammatory diseases
AMG 139 is a fully human monoclonal antibody. It is being investigated as a treatment for a variety of inflammatory disorders.
antibody
AMG 145
Hypercholesterolemia
AMG 145 is a fully human monoclonal antibody to Proprotein Convertase Subtilisin/Kexin Type 9 ("PCSK9"), a negative regulator of LDLR. AMG 145 is being investigated for the treatment of hypercholesterolemia.
antibody
AMG 151
Type 2 diabetes
AMG 151 is an orally-administered small molecule glucokinase activator. It reduces glucose levels via a dual mechanism of action - working in both the pancreas and the liver. It is being investigated as a treatment of type 2 diabetes. Amgen licensed this molecule from Array BioPharma Inc. in 2009.
antibody
AMG 157
Asthma
AMG 157 is a fully human monoclonal antibody that blocks the interaction of TSLP with TSLPR. AMG 157 is being investigated for its potential as a treatment for asthma.
antibody
AMG 167
Bone-related conditions
AMG 167 is a humanized monoclonal antibody that targets sclerostin, a protein secreted by bone cells that inhibits bone formation. AMG 167 is being developed in collaboration with UCB for bone-related conditions.
antibody
AMG 181
Ulcerative colitis
AMG 181 is a fully human monoclonal antibody. It is being investigated for the treatment of ulcerative colitis.
antibody
AMG 191
Inflammatory diseases
AMG 191 is a humanized anti-c-Kit monoclonal antibody that inhibits the binding of Stem Cell Factor ("SCF") to c-Kit. Inhibition of SCF binding may have potential therapeutic benefit in a variety of inflammatory diseases.
antibody
AMG 208
Various cancer types
AMG 208 is a small molecule inhibitor of c-Met that inhibits both ligand-dependent and ligand-independent c-Met activation. It is being investigated as a cancer treatment.
antibody
AMG 221
Type 2 diabetes
AMG 221 is an orally-administered small molecule antagonist of 11-beta hydroxysteroid dehydrogenase type 1 ("11ß-HSD1"), an enzyme associated with conversion of cortisone to cortisol in the liver and adipose tissue. It may have utility in a variety of metabolic and other disorders.
antibody
AMG 319
Hematologic malignancies
AMG 319 is an orally-administered small molecule inhibitor of PI3 Kinase δ. It is being investigated as a cancer treatment.
antibody
AMG 337
Various cancer types
AMG 337 is a selective inhibitor of c-Met, which inhibits multiple mechanisms of c-Met activation. It is being investigated as a cancer treatment.
antibody
AMG 557
Systemic lupus erythematosus
AMG 557 is a fully human monoclonal antibody that binds to B7 related protein ("B7RP-1"). It is being investigated for its utility in autoimmune diseases such as systemic lupus erythematosus.
antibody
AMG 745
Muscle-wasting disorders
AMG 745 is a peptibody that inhibits myostatin. It is being investigated for its utility to inhibit muscle loss associated with a variety of diseases and conditions.
antibody
AMG 747
Neuroscience
AMG 747 is a selective small molecule central glycine transporter type-1 ("GlyT-1") inhibitor. It is being investigated as treatment for the cognitive deficits associated with schizophrenia.
antibody
AMG 761
Asthma
AMG 761 is a humanized monoclonal antibody targeted to CCR4 positive T-cells. AMG 761 binding leads to depletion of CCR4 positive T-cells. AMG 761 is being investigated as a therapy for asthma. Amgen licensed this molecule from Kyowa Hakko Kirin Co., Ltd. in 2008.
antibody
AMG 780
Various cancer types
AMG 780 is a fully human anti-angiopoietin antibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
antibody
AMG 811
Systemic lupus erythematosus
AMG 811 is a fully human monoclonal antibody that binds to interferon gamma, a widely active pro-inflammatory cytokine. It is being investigated as a treatment for systemic lupus erythematosus.
antibody
AMG 820
Various cancer types
AMG 820 is a fully human monoclonal antibody that targets c-fms and decreases tumor associated macrophage ("TAM") function. It is being investigated as a cancer treatment.
antibody
AMG 888
Various cancer types
AMG 888 is a fully human monoclonal antibody that inhibits human epidermal growth factor receptor 3 ("HER3") oncogenic signaling. AMG 888 is being investigated as a cancer treatment. Amgen is developing this product in collaboration with Daiichi Sankyo.
antibody
AMG 900
Various cancer types
AMG 900 is an orally-administered small molecule inhibitor of Aurora kinases A, B, and C. It is being investigated as a cancer treatment.
antibody
Dulanermin (rhApo2L/TRAIL)
Various cancer types
Dulanermin is a recombinant human protein that targets death receptors 4 and 5 ("DR4" and "DR5") and induces apoptosis in sensitive tumor cells. It is being investigated as a cancer treatment. We are developing this molecule in collaboration with Genentech, a member of the Roche Group.
Phase 2
antibody
AMG 386
Various cancer types
AMG 386 is a peptibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
antibody
AMG 785
Bone-related conditions, including postmenopausal osteoporosis and fracture healing
AMG 785 is a humanized monoclonal antibody that targets sclerostin, a protein secreted by bone cells that inhibits bone formation. AMG 785 (also known as CDP7851) is being developed in collaboration with UCB for bone-related conditions, including postmenopausal osteoporosis and fracture healing.
antibody
AMG 827
Inflammatory diseases
AMG 827 is a fully human monoclonal antibody that binds to and blocks signaling via the interleukin-17 receptor. It is being investigated as a treatment for a variety of inflammatory disorders.
antibody
AMG 853
Asthma
AMG 853 is an orally-administered small molecule antagonist of the CRTH2 and D-prostanoid receptors of prostaglandin D2. It is being investigated as a treatment for asthma.
antibody
Conatumumab
Various cancer types
Conatumumab is a fully human monoclonal antibody agonist that targets death receptor 5 and induces apoptosis in sensitive tumor cells. It is being investigated as a cancer treatment.
antibody
Denosumab
Rheumatoid arthritis
Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.
antibody
Ganitumab
(AMG 479)
Various cancer types
Ganitumab (AMG 479) is a fully human monoclonal antibody antagonist of IGF-1 receptor. It is being investigated as a cancer treatment.
antibody
Motesanib
First-line breast cancer
Motesanib is an orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2 and 3, platelet-derived growth factor receptors and stem cell factor receptor. It is being investigated as a cancer treatment. We are developing this product in collaboration with Takeda/Millennium Pharmaceuticals.
antibody
Nplate® (romiplostim)
Chemotherapy-induced thrombocytopenia
Nplate® is a peptibody agonist of the thrombopoietin (TPO) receptor.
antibody
Nplate® (romiplostim)
Myelodysplastic syndromes
Nplate® is a peptibody agonist of the thrombopoietin (TPO) receptor.
antibody
Omecamtiv mecarbil
(AMG 423)
Heart failure
Omecamtiv mecarbil is a small molecule activator of cardiac myosin. Omecamtiv mecarbil is being investigated to improve cardiac contractility in subjects with heart failure. We are developing this product in collaboration with Cytokinetics, Inc. ("Cytokinetics").
antibody
Rilotumumab
(AMG 102)
Various cancer types
Rilotumumab (AMG 102) is a fully human monoclonal antibody that blocks the action of hepatocyte growth factor/scatter factor. It is being investigated as a cancer treatment.
antibody
Sensipar®/Mimpara® (cinacalcet)
Post renal transplant
Sensipar®/Mimpara® is an orally-administered small molecule that lowers parathyroid hormone ("PTH") levels in blood by signaling through the calcium-sensing receptor in parathyroid tissue to inhibit PTH secretion. It also lowers blood calcium and phosphorous levels.
antibody
Vectibix® (panitumumab)
Locally advanced head and neck cancer
Vectibix® is a monoclonal antibody antagonist of the epidermal growth factor receptor ("EGFr") pathway. It is being investigated as a cancer treatment.
Phase 3
antibody
AMG 386
Ovarian cancer
AMG 386 is a peptibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
antibody
Aranesp® (darbepoetin alfa)
Anemia in heart failure
Aranesp® is a recombinant human protein agonist of the erythropoietin receptor.
antibody
Ganitumab
(AMG 479)
Pancreatic cancer
Ganitumab (AMG 479) is a fully human monoclonal antibody antagonist of IGF-1 receptor. It is being investigated as a cancer treatment.
antibody
Motesanib
First-line non-small cell lung cancer
Motesanib is an orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2 and 3, platelet-derived growth factor receptors and stem cell factor receptor. It is being investigated as a cancer treatment. We are developing this product in collaboration with Takeda/Millennium Pharmaceuticals.
antibody
Prolia® (denosumab)
Male osteoporosis
Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.
antibody
Sensipar®/Mimpara® (cinacalcet)
Cardiovascular disease in patients with secondary hyperparathyroidism and chronic kidney disease undergoing maintenance dialysis
Sensipar®/Mimpara® is an orally-administered small molecule that lowers parathyroid hormone ("PTH") levels in blood by signaling through the calcium-sensing receptor in parathyroid tissue to inhibit PTH secretion. It also lowers blood calcium and phosphorous levels.
antibody
Vectibix® (panitumumab)
First- and second-line colorectal cancer
Vectibix® is a monoclonal antibody antagonist of the epidermal growth factor receptor ("EGFr") pathway. It is being investigated as a cancer treatment.
antibody
XGEVA™ (denosumab)
Prevention of bone metastases in breast cancer
Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.
antibody
XGEVA™ (denosumab)
Prevention of bone metastases in prostate cancer
Denosumab is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. Denosumab is being studied across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases.

Phase 3 pipeline update*

Added OncoVEXGM-CSF (talimogene laherparepvec), an oncolytic vaccine for the treatment of metastatic melanoma and head and neck cancer. Amgen acquired OncoVEX as part of its acquisition of BioVex Group, Inc., which closed March 4, 2011.

*Update to this phase 3 program occurred after February 9, 2011

 

 

Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.   
   
Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.   
   
Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.   
footer